French pharma major Sanofi (Euronext: SAN) and German peer Boehringer Ingelheim have signed contracts to secure the strategic transaction initiated in December 2015 which consists of an exchange of Sanofi's animal health business (Merial) and Boehringer's consumer healthcare (CHC) business.
This step marks a major milestone before closing of the transaction which is expected by year-end 2016 and remains subject to approval by all regulatory authorities in different territories. The integration of Boehringer’s CHC business into Sanofi and Merial into Boehringer would start after closing.On closing this transaction – with an asset value of around 22.8 billion euros ($25.3 billion) - will be a significant business swap in the pharmaceutical sector and an important event in the history of both companies. Market reaction to the deal was muted, as Sanofi’s shares gained just 0.65% to 69.9 euros by mid-morning in Paris.
Prof Dr Andreas Barner, chairman of the board of family-owned Boehringer Ingelheim, said: "This is a win for Boehringer Ingelheim and Sanofi alike. Moreover, it is one of the most significant steps in our corporate history. It demonstrates the consistent orientation of our business towards innovation-driven sectors. As a research based pharmaceutical company, we will substantially enhance our position in the future market for Animal Health and will prospectively be one of the largest global players in this segment. The similarity in culture and approaches of BI and Sanofi will ensure that the businesses acquired by the other partner will develop well in the future."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze